Back to Back Issues Page
AMD Research for a One Time Treatment
May 10, 2017

AMD Research for a One Time Treatment

What do the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology, and the American Society for Gene and Cell Therapy have in common?

Preclinical data from macular degeneration studies supported by REGENXBIO at the University of Pennsylvania’s Gene Therapy Program and Center for Advanced Retinal and Ocular Therapeutics and the Johns Hopkins Wilmer Eye Institute will be shared at each of these organizations' upcoming conferences.

Gene Therapy Research

Research using gene therapy to treat neovascular or wet macular degeneration works by delivering a gene that inhibits blood vessel growth that leads to leaking blood vessels under the retina which distorts one's vision leading to several different types of vision changes including the loss of one's central or straight ahead vision.

Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO states, “RGX-314 has the potential to be a one-time treatment for people with wet AMD by delivering high expression of anti-VEGF antibodies through the use of our NAV AAV8 vector. We are pleased to share additional positive preclinical results, which were generated by our development partners at the University of Pennsylvania and Johns Hopkins ...”

How does gene therapy work and who is a candidate for this type of macular degeneration research? Find out more ...

Gene Therapy for Macular Degeneration

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page